Liberate Bio
1 known investors
Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
BiotechDeep TechDigital HealthMedical Devices
Investors · 1
In the news
- Editor’s pick: Liberate Bio | Nature Biotechnologynature.com · 2026
- Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - BioSpacebiospace.com · 2026
- Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapiesendpoints.news · 2025
- Liberate Bio Raises $31M for In Vivo CAR-M Therapy, Targeting Safer Immune Reset | PackGene Biotechpackgene.com · 2025